How does the company's financial performance compare to that of its main competitors in the biotech/pharmaceutical sector?

Short answer:

The press‑release you provided only announces that Zealand Pharma will hold a conference call on 14 August 2025 to present its second‑quarter 2025 earnings. It does not disclose any financial figures, growth metrics, profit‑or‑loss data, or other performance‑related information. Consequently, with the information supplied in this announcement, we cannot directly compare Zealand Pharma’s financial performance to that of its main competitors in the biotech/pharmaceutical sector.

Why a direct comparison isn’t possible from this release

Because none of the above data points appear in the press‑release, any quantitative or even qualitative assessment of how Zealand Pharma is performing relative to its rivals (e.g., Amgen, Biogen, Gilead, Regeneron, etc.) is impossible at this stage.

What you would normally look at (if the data were available)

1. Revenue & Growth – Compare Q2 2025 revenue and YoY growth percentages to peer companies’ Q2 results (e.g., Amgen’s Q2 revenue vs. Zealand’s revenue).
2. Profitability – Net profit margin, EPS, and operating margin relative to the sector’s averages.
3. R&D Intensity – R&D expense as a % of revenue (a key metric in biotech) compared to peers.
4. Cash Position – Cash and equivalents on the balance sheet, burn rate, and runway versus competitors.
5. Product Pipeline & Milestones – Progress on key product candidates (e.g., GLP‑1 analogues, rare‑disease therapies) compared with competitor pipelines.
6. Valuation & Market Perception – Share price performance around earnings release, P/E ratio, and analyst sentiment relative to the biotech index.

How to obtain the needed comparison

1. Wait for the earnings call (14 Aug 2025) or the accompanying earnings release (usually posted a few days after the call).
   
2. Collect peer data from the same period (e.g., Amgen’s Q2 2025 results released in early August 2025). Use sources such as:
   
   • SEC 10‑Q/10‑K filings.
     
   • Bloomberg/FactSet/Refinitiv for financial summaries.
     
   • Analyst research notes (e.g., from JPMorgan, Credit Suisse, or boutique biotech analysts).
     
3. Prepare a side‑by‑side table with the key metrics listed above to show where Zealand stands (e.g., revenue growth of +12 % vs. industry average +8 %, R&D spend 18 % of revenue vs. 22 % industry average, etc.).
   
4. Interpret the results:
   
   • If Zealand’s revenue growth outpaces peers but profitability lags, discuss potential drivers (e.g., higher R&D spend, early‑stage pipeline).
     
   • If cash burn is higher, examine financing needs vs. peers.
     
   • Relate any differences to strategic choices (e.g., focus on orphan drugs, licensing deals, or collaborations).

Bottom line

• From the current announcement: No financial data are available, so a direct performance comparison cannot be made.
• Next steps: Obtain the actual Q2 2025 earnings data from the upcoming conference call (or the formal earnings release) and then benchmark against peer results from the same quarter using the metrics outlined above. Once those numbers are in hand, a robust, data‑driven comparison to the main competitors in the biotech/pharmaceutical sector can be performed.